KR20110115803A - Compositions for external application to the skin having a promotion activity of collagen synthesis - Google Patents

Compositions for external application to the skin having a promotion activity of collagen synthesis Download PDF

Info

Publication number
KR20110115803A
KR20110115803A KR1020100035335A KR20100035335A KR20110115803A KR 20110115803 A KR20110115803 A KR 20110115803A KR 1020100035335 A KR1020100035335 A KR 1020100035335A KR 20100035335 A KR20100035335 A KR 20100035335A KR 20110115803 A KR20110115803 A KR 20110115803A
Authority
KR
South Korea
Prior art keywords
skin
composition
collagen
present
extract
Prior art date
Application number
KR1020100035335A
Other languages
Korean (ko)
Other versions
KR101261731B1 (en
Inventor
현창구
문지영
김동삼
함영민
표형배
이근수
김경범
이욱재
이남호
Original Assignee
재단법인 제주테크노파크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 재단법인 제주테크노파크 filed Critical 재단법인 제주테크노파크
Priority to KR1020100035335A priority Critical patent/KR101261731B1/en
Publication of KR20110115803A publication Critical patent/KR20110115803A/en
Application granted granted Critical
Publication of KR101261731B1 publication Critical patent/KR101261731B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706Algae
    • A61K8/9711Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02Algae
    • A61K36/03Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)

Abstract

본 발명은 경단구슬모자반 추출물을 유효성분으로 포함하는 콜라겐 생성 촉진용 피부 외용제 조성물을 개시한다.The present invention discloses a composition for external skin preparation for promoting collagen production, which comprises an extract as a active ingredient.

Description

콜라겐 생성 촉진용 피부 외용제 조성물{Compositions for External Application to the Skin Having a Promotion Activity of Collagen Synthesis}Composition for external application to promote collagen production {Compositions for External Application to the Skin Having a Promotion Activity of Collagen Synthesis}

본 발명은 콜라겐 생성 촉진용 피부 외용제 조성물에 관한 것이다. 구체적으로 본 발명은 경단구슬모자반(Sargassum muticum) 추출물을 이용한 콜라겐 생성 촉진용 피부 외용제 조성물에 관한 것이다.
The present invention relates to an external preparation composition for promoting collagen production. Specifically, the present invention is a ball dan ball hat ( Sargassum) Muticum ) relates to an external composition for skin promotion for collagen production using the extract.

콜라겐은 피부의 섬유아세포에서 생성 분비되는 불용성 가교 단백질로서 세포외 간질에 존재하고, 생체 단백질 총 중량의 30%를 차지한다. Collagen is an insoluble crosslinked protein produced and secreted by the fibroblasts of the skin and is present in extracellular epilepsy and accounts for 30% of the total weight of biological proteins.

콜라겐은 피부, 뼈, 연골, 혈관 등을 형성하는 주요 섬유성 단백질이며, 피부의 기계적 견고성, 결합조직의 저항력과 조직의 결합력, 세포 접착의 지탱, 세포분할과 분화의 유도 등이 그 주요한 기능으로 알려져 있다(Ann N Y Acad Sci. 1990;580:8-16).Collagen is a major fibrous protein that forms skin, bones, cartilage, blood vessels, etc.The main functions are collagen's mechanical strength, resistance of connective tissue and tissue binding, support of cell adhesion, induction of cell division and differentiation. It is known ( Ann NY Acad Sci . 1990; 580: 8-16).

특히 콜라겐은 진피층의 90% 이상을 구성하고 있어, 자외선, 스트레스, 활성 산소 등에 의하여 콜라겐이 파괴되면, 피부 탄력성이 감소하고 피부 주름이 발생하게 된다(Arch Dermatol. 1989;125(8):1150). 또한 콜라겐은 자체 수분 보유력을 가지기 때문에 콜라겐이 파괴되면 피부는 건조하고 거칠어지게 된다(J Ginseng Res 31(2):86-92, 2007; Toxicol Appl Pharmacol 195: 298-308, 2004).In particular, collagen is composed of more than 90% of the dermal layer, when collagen is destroyed by ultraviolet rays, stress, free radicals, etc., the skin elasticity is reduced and skin wrinkles occur (Arch Dermatol. 1989; 125 (8): 1150). In addition, collagen has its own water retention, so when collagen is destroyed, the skin becomes dry and rough (J Ginseng Res 31 (2): 86-92, 2007;Toxicol Appl Pharmacol 195: 298-308, 2004).

따라서 콜라겐 생합성 촉진 물질은 화장품 원료로서 피부 주름을 방지하고 피부의 건조함을 개선하는 데 유용할 수 있다. Thus, collagen biosynthesis promoting material may be useful as a cosmetic raw material to prevent skin wrinkles and improve the dryness of the skin.

이러한 이유에서 콜라겐 생합성 촉진 물질을 찾고자 하는 노력이 이루어지고 있다. 예컨대 대한민국 공개 특허 제2009-0110726호는 콜라겐 생성 촉진 활성을 가지는 알로에 베라 겔의 한외 여과 투과액을 개시하고 있고, 대한민국 공개특허 2006-0037245호는 콜라겐 생성 촉진 활성을 가지는 우유 유래 염기성 단백질 분획 또는 여기에 단백가수분해효소를 처리한 염기성 펩티드 분획을 개시하고 있다.For this reason, efforts have been made to find collagen biosynthesis promoting substances. For example, Korean Patent Publication No. 2009-0110726 discloses an ultrafiltration permeate of aloe vera gel having collagen production promoting activity, and Korean Patent Laid-Open Publication No. 2006-0037245 discloses a milk-derived basic protein fraction or excitation having collagen production promoting activity. Discloses a basic peptide fraction treated with proteolytic enzymes.

본 발명도 콜라겐 생성 촉진 활성을 가지는 경단구슬모자반 추출물을 개시한다.
The present invention also discloses a dumpling bead cap extract having collagen production promoting activity.

본 발명의 목적은 콜라겐 생성 촉진용 피부 외용제 조성물을 제공하는 데 있다.An object of the present invention is to provide an external composition for skin for promoting collagen production.

본 발명의 다른 목적이나 구체적인 양태는 이하에서 제시될 것이다.
Other objects or specific aspects of the present invention will be presented below.

본 발명자들은 아래의 실험예에서 확인되듯이, 경단구슬모자반의 열수 추출물을 사람의 섬유아세포 CCD-986SK에 처리할 경우 타입 Ⅰ콜라겐(type Ⅰ collagen)의 생합성이 촉진됨을 확인할 수 있었다. 타입 Ⅰ콜라겐은 피부 탄력 및 피부 보습과 밀접한 관련성을 가지는 것으로 보고되어 있는 콜라겐이다(J. Inv . Der., 98; 248-254, 1992; Arch Dermatol 138: 1462-1470, 2002). 아래의 실험예에서 상기 경단구슬모자반 추출물의 콜라겐 생합성 촉진 효과는 세포 증식 촉진 효과에 기인한 것이 아님을 확인할 수 있다.The present inventors confirmed that the biosynthesis of type I collagen is promoted when the hydrothermal extract of the transdermal bead capsula is treated with human fibroblast CCD-986SK, as confirmed in the following experimental example. Type I collagen is a collagen that has been reported to be closely associated with skin elasticity and skin moisturization ( J. Inv . Der. , 98; 248-254, 1992; Arch Dermatol 138: 1462-1470, 2002). In the following experimental example, it can be confirmed that the collagen biosynthesis promoting effect of the light bulb bead capillary extract is not due to the cell proliferation promoting effect.

본 발명은 이러한 실험 결과에 기초하여 완성된 것으로, 본 발명의 콜라겐 생성 촉진용 피부 외용제 조성물은 경단구슬모자반 추출물을 유효성분으로 포함함을 특징으로 한다.The present invention was completed based on the results of these experiments, the composition for promoting external collagen production of the present invention is characterized in that it comprises a dumpling bead capillary extract as an active ingredient.

본 명세서에서, "콜라겐 생성 촉진용"의 의미는 전술한 바와 같이 콜라겐의 양이 피부 주름 및 피부 보습과 밀접한 상관성을 가지므로, "피부 주름 개선용" 및/또는 "피부 보습용"의 의미를 포함하는 의미이다. 따라서 상기 경단구슬모자반 추출물을 유효성분으로 포함하는 피부 주름 개선용 피부 외용제 조성물 및/또는 상기 경단구슬모자반 추출물을 유효성분으로 포함하는 피부 보습용 피부 외용제 조성물도 본 발명의 콜라겐 생성 촉진용 조성물에 포함하는 것으로 이해된다. In the present specification, the meaning of "promoting collagen production" includes the meaning of "for improving skin wrinkles" and / or "for moisturizing skin," as described above, since the amount of collagen has a close correlation with skin wrinkles and skin moisturizing. I mean. Therefore, the skin external preparation composition for improving skin wrinkles comprising the dandelion bead capillary extract as an active ingredient and / or the skin external preparation composition for moisturizing the skin comprising the extract as an active ingredient is also included in the composition for promoting collagen production of the present invention. It is understood that.

또 본 명세서에서, "경단구슬모자반 추출물"은 추출 방법을 불문하고 추출 대상인 경단구슬모자반을 메탄올, 증류수, 에탄올, 아세톤, 에틸아세테이트, 포화노말부탄올, 클로로포름, 메틸렌클로라이드, 물, 또는 이들의 혼합 용매로 추출하여 얻어진 조추출물과 그 조추출물을 상기 열거된 용매로 분획하여 얻어진 추출물을 포함하는 의미로서 이해된다. 추출 방법을 불문하므로, 추출 대상을 추출 용매에 침지시키는 단계를 통하여 추출되는 한, 추출 방법은 냉침, 환류, 가온, 초음파 방사 등 임의의 방식이 모두 적용될 수 있다. 그럼에도 상기 "경단구슬모자반 추출물"은 바람직하게는 추출 대상인 경단구슬모자반을 물, 증류수, 에탄올 또는 이들의 혼합 용매로 추출하여 얻어진 추출물을 말한다. 이러한 추출물은 추출 용매가 제거된 액상의 농축물이거나 고형물일 수 있다.In addition, in the present specification, "light bulb bead cap extract" regardless of the extraction method is used to extract the light bulb bead cap is methanol, distilled water, ethanol, acetone, ethyl acetate, saturated normal butanol, chloroform, methylene chloride, water, or a mixed solvent thereof The crude extract obtained by extraction with the crude extract and the crude extract is understood as meaning including the extract obtained by fractionation with the solvents listed above. Regardless of the extraction method, as long as the extraction object is extracted through the step of immersing in the extraction solvent, the extraction method may be any method such as cooling, refluxing, heating, ultrasonic radiation, and the like. Nevertheless, the "single bead hat jar extract" refers to an extract obtained by extracting the bead bead hat jar to be extracted with water, distilled water, ethanol or a mixed solvent thereof. Such extracts may be liquid concentrates or solids from which the extraction solvent has been removed.

또한 본 명세서에서 "유효성분"이란 단독으로 목적하는 활성을 나타내거나 또는 그 자체는 활성이 없는 담체와 함께 활성을 나타낼 수 있는 성분을 의미한다.In addition, the term "active ingredient" as used herein means a component that can exhibit the desired activity alone or in combination with a carrier that is not active itself.

본 명세서에서 특별히 정의되지 아니한 기타의 용어는 국어사전적 의미나 당업계에서 일반적으로 받아들여지고 있는 의미를 따른다.Other terms that are not specifically defined herein follow the Korean dictionary meaning or the meaning generally accepted in the art.

한편 본 발명의 콜라겐 생합성 촉진용 조성물은 그 유효성분인 경단구슬모자반 추출물을 콜라겐 생합성 촉진 활성을 나타낼 수 있는 한 용도, 제형, 배합 목적 등에 따라 임의의 양(유효량)으로 포함할 수 있는데, 통상적인 유효량은 조성물 전체 중량을 기준으로 할 때 0.001 중량 % 내지 20.000 중량 % 범위 내에서 결정될 것이다. 여기서 "유효량"이란 콜라겐의 생합성을 촉진할 수 있는 유효성분의 양을 말한다. 이러한 유효량은 당업자의 통상의 능력 범위 내에서 실험적으로 결정될 수 있다.On the other hand, the composition for promoting collagen biosynthesis of the present invention may include an effective ingredient, such as hardwood bead capsular extract, in any amount (effective amount) depending on the purpose, formulation, formulation purpose, etc., as long as it can exhibit collagen biosynthesis promoting activity. An effective amount will be determined within the range of 0.001% to 20.000% by weight, based on the total weight of the composition. Here, "effective amount" refers to the amount of the active ingredient that can promote the biosynthesis of collagen. Such effective amounts can be determined experimentally within the range of ordinary skill in the art.

본 발명의 콜라겐 생합성 촉진용 피부 외용제 조성물은 구체적인 양태에 있어서 화장품 조성물로 파악할 수 있다.The external preparation composition for promoting collagen biosynthesis of the present invention can be understood as a cosmetic composition in a specific embodiment.

본 발명의 조성물이 화장품 조성물로서 파악될 경우, 그 화장품 조성물은 다양한 형태로 제조될 수 있는데, 예컨대, 에멀젼, 로션, 크림(수중유적형, 유중수적형, 다중상), 용액, 현탁액(무수 및 수계), 무수 생성물(오일 및 글리콜계), 젤, 마스크, 팩, 분말 등의 제형으로 제조될 수 있다.When the composition of the present invention is conceived as a cosmetic composition, the cosmetic composition can be prepared in various forms, for example, emulsions, lotions, creams (oil-in-water, water-in-oil, multiphase), solutions, suspensions (anhydrous and Aqueous), anhydrous products (oil and glycol based), gels, masks, packs, powders and the like.

본 발명의 조성물은 그 유효성분을 포함하는 이외에 화장품 제제에 있어서 수용가능한 담체를 포함할 수 있다. The composition of the present invention may include an acceptable carrier in a cosmetic preparation in addition to including the active ingredient.

여기서 "화장품 제제에 있어서 수용가능한 담체"란 화장품 제제에 포함될 수 있는 이미 공지되어 사용되고 있는 화합물 또는 조성물이거나 앞으로 개발될 화합물 또는 조성물로서 피부와의 접촉시 인체가 적응 가능한 이상의 독성을 지니지 않는 것을 말한다.Herein, "acceptable carrier in cosmetic preparation" means a compound or composition already known and used that can be included in cosmetic preparations or a compound or composition which will be developed in the future and does not have more toxicity than the body can adapt to when contacted with the skin.

상기 담체는 본 발명의 조성물에 그것의 전체 중량에 대하여 약 1 중량 % 내지 약 99.99 중량 %, 바람직하게는 조성물의 중량의 약 50 중량% 내지 약 99 중량 %로 포함될 수 있다. The carrier may be included in the composition of the present invention from about 1% to about 99.99% by weight, preferably from about 50% to about 99% by weight of the composition.

그러나 상기 비율은 화장품의 전술한 바의 제형에 따라 또 그것의 구체적인 적용 부위(얼굴이나 손)나 그것의 바람직한 적용량 등에 따라 달라지는 것이기 때문에, 상기 비율은 어떠한 측면으로든 본 발명의 범위를 제한하는 것으로 이해되어서는 안 된다. However, it is understood that the ratios limit the scope of the present invention in any aspect because the ratios vary depending on the formulation of the cosmetics as described above and their specific application site (face or hand) or their preferred application amount. It should not be.

한편, 상기 담체로서는 알코올, 오일, 계면활성제, 지방산, 실리콘 오일, 습윤제, 보습제, 점성 변형제, 유제, 안정제, 자외선 차단제, 발색제, 향료 등이 예시될 수 있다. Meanwhile, examples of the carrier include alcohols, oils, surfactants, fatty acids, silicone oils, wetting agents, moisturizers, viscosity modifiers, emulsions, stabilizers, sunscreen agents, colorants, fragrances, and the like.

상기 담체로서 사용될 수 있는 알코올, 오일, 계면활성제, 지방산, 실리콘 오일, 습윤제, 보습제, 점성 변형제, 유제, 안정제, 자외선 차단제, 발색제, 향료 로 사용될 수 있는 화합물/조성물 등은 이미 당업계에 공지되어 있기 때문에 당업자라면 적절한 해당 물질/조성물을 선택하여 사용할 수 있다.Alcohols, oils, surfactants, fatty acids, silicone oils, wetting agents, humectants, viscosity modifiers, emulsions, stabilizers, sunscreens, colorants, compounds / compositions that can be used as fragrances, etc., which can be used as the carrier are already known in the art. As a result, those skilled in the art can select and use appropriate materials / compositions.

본 발명의 조성물은 또 다른 구체적인 양태에 있어 비누 조성물로서 파악될 수 있다.The composition of the present invention may be regarded as a soap composition in another specific embodiment.

본 발명의 조성물이 비누 조성물로서 파악될 경우에, 본 발명의 비누 조성물은 비누 기재에 그 유효성분을 포함하여 제조될 수 있으며, 첨가제로서 피부 보습제, 유화제, 경수 연화제 등을 포함하여 제조될 수 있다.When the composition of the present invention is understood as a soap composition, the soap composition of the present invention may be prepared by including an active ingredient thereof in a soap base, and may be prepared by including a skin moisturizer, an emulsifier, a hard water softener, and the like as an additive. .

상기 비누 기재로서는 야자유, 팜유, 대두유, 파마자유, 올리브유, 팜핵류 등의 식물유지 또는 우지, 돈지, 양지, 어유 등의 동물유지 등이 사용될 수 있고, 상기 피부 보습제로서는 글리세린, 에리트리톨, 폴리에틸렌글리콜, 프로필렌글리콜, 부틸렌글리콜, 펜틸렌글리콜, 헥실글리콜, 이소프로필미리스테이트, 실리콘 유도체, 알로에베라, 솔비톨 등이 사용될 수 있으며, 상기 유화제로서는 천연오일, 왁스 지방알콜, 탄화수소류, 천연식물 추출물 등이 사용될 수 있고, 상기 경수연화제로서는 테트라소듐 이디티에이 등이 사용될 수 있다.As the soap base material, vegetable oils such as palm oil, palm oil, soybean oil, perm oil, olive oil, palm kernels, or animal oils such as tallow, pork, sunny and fish oils can be used, and the skin moisturizing agent is glycerin, erythritol and polyethylene glycol. , Propylene glycol, butylene glycol, pentylene glycol, hexyl glycol, isopropyl myristate, silicone derivatives, aloe vera, sorbitol and the like can be used, the emulsifiers include natural oils, wax fatty alcohols, hydrocarbons, natural plant extracts, etc. May be used, and tetrasodium idieti or the like may be used as the water softener.

본 발명의 비누 조성물은 또한 첨가제로서 항균제, 분산제, 거품억제제, 용매, 물때 방지제, 부식 방지제, 향료, 색소, 금속이온 봉쇄제, 산화방지제, 방부제 등을 추가적으로 포함할 수 있다.The soap composition of the present invention may further include an antimicrobial agent, a dispersant, a foam inhibitor, a solvent, a scale inhibitor, a corrosion inhibitor, a perfume, a pigment, a metal ion sequestrant, an antioxidant, a preservative, and the like as an additive.

본 발명의 비누 조성물에 있어서, 비누 기재나 첨가제는 당업계에 일반적으로 사용되고 있는 함량으로 포함될 수 있는데, 비누 기재는 일반적으로 비누 조성물의 전체 중량을 기준으로 하였을 때 99 중량% 내지 50 중량%로 첨가될 수 있으며, 첨가제는 1 중량% 내지 20 중량%로 첨가될 수 있다. In the soap composition of the present invention, the soap base or additives may be included in an amount generally used in the art, and the soap base is generally added in an amount of 99% to 50% by weight based on the total weight of the soap composition. The additive may be added in an amount of 1% to 20% by weight.

본 발명의 조성물은 다른 구체적인 양태에 있어서 약제학적 조성물로 파악될 수 있다.The composition of the present invention may be regarded as a pharmaceutical composition in another specific embodiment.

본 발명의 약제학적 조성물은 그 유효성분 이외에 약제학적으로 허용되는 담체, 부형제 등을 포함하여, 국소형 제형 예컨대 크림, 로션, 연고(반고형의 외용약), 마이크로로에멀젼, 젤, 페이스트, 경피제제(TTS)(예컨대 패치제, 붕대 등) 등으로 제조될 수 있다.The pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier, excipient, and the like in addition to the active ingredient, and may be a topical formulation such as creams, lotions, ointments (semi-solid external preparations), micro-emulsions, gels, pastes, transdermal preparations. (TTS) (such as patches, bandages, etc.) and the like.

상기에서 "약제학적으로 허용되는" 의미는 유효성분의 활성을 억제하지 않으면서 적용(처방) 대상이 적응가능한 이상의 독성을 지니지 않는다는 의미이다.As used herein, "pharmaceutically acceptable" means that the subject of application (prescription) is not as toxic as applicable, without inhibiting the activity of the active ingredient.

약제학적으로 허용되는 담체의 예로서는 락토스, 글루코스, 슈크로스, 전분(예컨대 옥수수 전분, 감자 전분 등), 셀룰로오스, 그것의 유도체(예컨대 나트륨 카르복시메틸 셀룰로오스, 에틸셀룰로오스, 등), 맥아, 젤라틴, 탈크, 고체 윤활제(예컨대 스테아르산, 스테아르산 마그네슘 등), 황산 칼슘, 식물성 기름(예컨대 땅콩 기름, 면실유, 참기름, 올리브유 등), 폴리올(예컨대 프로필렌 글리콜, 글리세린 등), 알긴산, 유화제(예컨대 TWEENS), 습윤제(예컨대 라우릴 황산 나트륨), 착색제, 풍미제, 안정화제, 항산화제, 보존제, 물, 식염수, 인산염 완충 용액 등을 들 수 있다. 이러한 담체는 본 발명의 약제학적 조성물의 제형에 따라 적당한 것을 하나 이상 선택하여 사용할 수 있다.Examples of pharmaceutically acceptable carriers include lactose, glucose, sucrose, starch (such as corn starch, potato starch, etc.), cellulose, derivatives thereof (such as sodium carboxymethyl cellulose, ethylcellulose, etc.), malt, gelatin, talc, Solid lubricants (such as stearic acid, magnesium stearate, etc.), calcium sulfate, vegetable oils (such as peanut oil, cottonseed oil, sesame oil, olive oil, etc.), polyols (such as propylene glycol, glycerin, etc.), alginic acid, emulsifiers (such as TWEENS), wetting agents (Such as sodium lauryl sulfate), colorants, flavors, stabilizers, antioxidants, preservatives, water, saline, phosphate buffer solutions, and the like. The carrier may be selected from one or more of suitable pharmaceutical formulations according to the formulation of the pharmaceutical composition of the present invention.

부형제도 본 발명의 약제학적 조성물의 제형에 따라 적합한 것을 선택하여 사용할 수 있는데, 예컨대 나트륨 카르복시메틸 셀룰로오스, 메틸 셀룰로오스, 히드로프로필메틸셀룰로오스, 알긴산 나트륨, 폴리비닐피롤리돈 등의 현탁제나 분산제 등을 들 수 있다. Excipients may be selected and used according to the formulation of the pharmaceutical composition of the present invention, for example, suspending agents and dispersants such as sodium carboxymethyl cellulose, methyl cellulose, hydropropylmethyl cellulose, sodium alginate, polyvinylpyrrolidone, etc. Can be.

본 발명의 약제학적 조성물은 경구 또는 비경구로 투여될 수 있고, 바람직하게는 국소적으로 투여될 수 있다.The pharmaceutical composition of the present invention may be administered orally or parenterally, preferably topically.

본 발명의 약제학적 조성물은 그 1일 투여량이 통상 0.001 ~ 150 mg/kg 체중 범위이고, 1회 또는 수회로 나누어 투여할 수 있다. 그러나, 본 발명의 약제학적 조성물의 투여량은 투여 경로, 환자의 연령, 성별, 체중, 환자의 중증도 등의 여러 관련 인자에 비추어 결정되는 것이므로 상기 투여량은 어떠한 측면으로든 본 발명의 범위를 제한하는 것으로 이해되어서는 아니 된다.
The daily dosage of the pharmaceutical composition of the present invention is usually 0.001 ~ 150 mg / kg body weight range, it can be administered once or divided into several times. However, since the dosage of the pharmaceutical composition of the present invention is determined in view of various related factors such as the route of administration, the age, sex, weight of the patient, and the severity of the patient, the dosage may limit the scope of the present invention in any aspect. It should not be understood as.

전술한 바와 같이, 본 발명에 따르면 콜라겐 생성 촉진용 피부 외용제 조성물을 제공할 수 있다. 본 발명의 콜라겐 생성 촉진 조성물은 피부 주름 개선 용도 또는 피부 보습 용도로 사용될 수 있으며, 화장품, 비누 등으로 제품화될 수 있다.
As described above, according to the present invention, it is possible to provide an external preparation composition for promoting collagen production. Collagen production promoting composition of the present invention can be used for skin wrinkle improvement or skin moisturizing use, it can be commercialized in cosmetics, soap and the like.

이하 본 발명을 실시예 및 실험예를 참조하여 설명한다. 그러나 본 발명의 범위가 이러한 실시예 및 실험예에 한정되는 것은 아니다.
Hereinafter, the present invention will be described with reference to Examples and Experimental Examples. However, the scope of the present invention is not limited to these examples and experimental examples.

<< 실시예Example > > 경단구슬모자반Dumpling ball hat 추출물 제조 Extract manufacturer

경단구슬모자반의 건조된 시료에 시료 무게 10배의 정제수를 넣고 100℃에서 4시간 동안 열수추출한 후 추출 잔사를 제거하고, 감암농축하여 추출 용매를 제거하였다. 시료는 물에 녹여 사용하였다.
Purified water of 10 times the weight of the sample was added to the dried sample of the hard bead cap, and hot water was extracted at 100 ° C. for 4 hours, and then the extraction residue was removed. The sample was dissolved in water and used.

<< 실험예Experimental Example > > 콜라겐 생합성 촉진 활성 실험 및 피부 주름 개선 임상실험Collagen biosynthesis promoting activity experiment and skin wrinkle improvement clinical trial

<< 실험예Experimental Example 1>  1> 콜라겐 생합성 촉진 활성 실험Collagen Biosynthesis Promoting Activity Experiment

<1> 세포 배양 <1> cell culture

실험에 사용한 사람의 섬유아세포(CCD-986SK, human fibroblasts)는 American Type Culture Collection (ATCC, Rockville,. USA)에서 구입하였으며, 10%의 FBS(fetal bovine serum, Hyclone)와 1% Antibiotic-Antimycotic(Gibco)이 첨가된 DMEM(Dulbecco's Modified Eagle Medium.Hyclone)으로 37℃, 5% CO2 조건에서 배양하였다. Human fibroblasts (CCD-986SK, human fibroblasts) used in the experiment were purchased from the American Type Culture Collection (ATCC , Rockville, USA), 10% FBS (fetal bovine serum, Hyclone) and 1% Antibiotic-Antimycotic ( Cultured at 37 ° C., 5% CO 2 conditions with DMEM (Dulbecco's Modified Eagle Medium.Hyclone) added with Gibco).

<2> Type I collagen 합성 촉진 효과 실험 <2> Type I collagen synthesis promoting effect experiment

사람 섬유아세포를 2×104cell/well 농도로 96 well에 분주한 다음, 24시간 배양하였다. 배지를 버리고 serum free 배지로 시료를 희석하여 13, 25, 50, 100, 및 200㎍/ml농도로 넣고 24시간 배양하였다. 배양액을 수거하여 실험에 사용하였으며, 세포 배양액 내 콜라겐 합성량은 procollagen type I peptide EIA kit(Takara Biomedical Co.)를 사용하여 측정하였다. Anticody-POD conjugate solution 100 μl를 각 well에 넣은 다음 sample 및 standard 20 μl를 넣고 37℃에서 3시간 배양하였다. 반응이 끝나면 각 well에 배양액을 제거한 뒤 PBS(phosphate buffered saline) 400 μl로 4회 세척하였다. 기질용액 100 μl를 첨가하고 상온에서 15분간 반응시켰다. stop solution(1N H2SO4) 100 μl를 첨가하여 반응을 중지시킨 후 ELISA reader로 450nm에서 흡광도를 측정하였다. 표준농도곡선을 작성하여 콜라겐 양을 확인하였다. Human fibroblasts were dispensed into 96 wells at a concentration of 2 × 10 4 cells / well and incubated for 24 hours. The medium was discarded and the sample was diluted with serum free medium and added to 13, 25, 50, 100, and 200 µg / ml concentrations and incubated for 24 hours. Cultures were collected and used for experiments, and collagen synthesis in cell cultures was measured using a procollagen type I peptide EIA kit (Takara Biomedical Co.). 100 μl of Anticody-POD conjugate solution was added to each well, and then 20 μl of sample and standard were added and incubated at 37 ° C. for 3 hours. After the reaction, the culture solution was removed from each well and washed four times with 400 μl of PBS (phosphate buffered saline). 100 μl of substrate solution was added and reacted at room temperature for 15 minutes. After stopping the reaction by adding 100 μl of stop solution (1N H 2 SO 4 ), the absorbance was measured at 450 nm with an ELISA reader. A standard concentration curve was prepared to check the amount of collagen.

결과를 <도 1>에 나타내었는데, 처리 농도가 50㎍/ml 이상에서는 유의적으로 콜라겐의 생합성을 촉진시킴을 보여준다. The results are shown in FIG. 1, which shows that the treatment concentration significantly promotes biosynthesis of collagen at 50 μg / ml or more.

<3> 세포 생존율 평가 실험 <3> cell viability evaluation experiment

사람 섬유아세포를 2×104cell/well 농도로 96 well에 분주한 다음 세포 배양 조건에서 24시간 배양한다. 배지를 버리고 serum free 배지로 시료를 희석하여 13, 25, 50, 100, 및 200㎍/ml 농도로 처리하고 24시간 배양하였다. MTT 용액(2mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl-2H-tetrazolium bromid 액)을 각 well에 50ul씩 넣고 4시간 동안 배양한다. 배양액을 제거한 다음 DMSO(dimethyl sulfoxide) 용액을 넣고, 10분간 흔들어 준 후 ELISA reader로 540nm에서 흡광도를 측정하였다.Human fibroblasts are dispensed into 96 wells at a concentration of 2 × 10 4 cells / well and incubated for 24 hours under cell culture conditions. The media was discarded and the samples were diluted with serum free media, treated with 13, 25, 50, 100, and 200 μg / ml concentrations and incubated for 24 hours. MTT solution (2mg / ml 3- (4,5-dimethylthiazol-2-yl) -2,5 diphenyl-2H-tetrazolium bromid solution) was added to each well of 50ul and incubated for 4 hours. After removing the culture solution, dimethyl sulfoxide (DMSO) solution was added, the solution was shaken for 10 minutes, and the absorbance was measured at 540 nm using an ELISA reader.

결과를 상기 타입 Ⅰ 콜라겐 생성 촉진 효과 실험 결과와 함께 <도 1>에 나타내었다. The results are shown in FIG. 1 along with the results of the type I collagen production promoting effect experiment.

<도 1>의 결과를 보면, 경단구슬모자반의 콜라겐 생합성 촉진 효과가 세포 증식에 따른 효과가 아님을 알 수 있다.
From the results of Figure 1, it can be seen that the collagen biosynthesis promoting effect of the dandelion bead hatchban is not an effect of cell proliferation.

통계처리Statistical processing

효과 판정을 위해 one way ANOVA test를 이용하였고 사후검정을 위해 대조군과 비교하는 Dunnett's post hoc test를 사용하였다(* P<0.05, ** P<0.01)One way ANOVA test was used to determine the effect, and Dunnett's post hoc test was compared to the control group for post test ( * P <0.05, ** P <0.01 ).

Claims (6)

경단구슬모자반 추출물을 유효성분으로 포함하는 콜라겐 생성 촉진용 피부 외용제 조성물.
Skin external composition for promoting collagen production, comprising a dumpling bead cap extract as an active ingredient.
제1항에 있어서,
상기 추출물은 경단구슬모자반을 물, 에탄올 또는 이들의 혼합 용매로 추출하여 얻어진 것을 특징으로 하는 콜라겐 생성 촉진용 피부 외용제 조성물.
The method of claim 1,
The extract is a skin external composition for promoting collagen production, characterized in that obtained by extracting the dumpling bead caps with water, ethanol or a mixed solvent thereof.
제1항에 있어서,
상기 콜라겐 생성 촉진용 피부 외용제 조성물은 피부 주름 개선 또는 피부 보습 용도로 사용되는 것을 특징으로 하는 콜라겐 생성 촉진용 피부 외용제 조성물.
The method of claim 1,
The skin external preparation composition for promoting collagen production is a skin external preparation composition for promoting collagen production, characterized in that it is used for skin wrinkle improvement or skin moisturizing use.
제1항 내지 제3항 중 어느 한 항에 있어서,
상기 조성물은 화장품 조성물인 것을 특징으로 하는 피부 외용제 조성물.
4. The method according to any one of claims 1 to 3,
The composition for external application for skin, characterized in that the cosmetic composition.
제1항 내지 제3항 중 어느 한 항에 있어서,
상기 조성물은 비누 조성물인 것을 특징으로 하는 피부 외용제 조성물.
4. The method according to any one of claims 1 to 3,
The composition for external application for skin, characterized in that the soap composition.
제1항 내지 제3항 중 어느 한 항에 있어서,
상기 조성물은 약제학적 조성물인 것을 특징으로 하는 피부 외용제 조성물.
4. The method according to any one of claims 1 to 3,
The composition for external application of skin, characterized in that the pharmaceutical composition.
KR1020100035335A 2010-04-16 2010-04-16 Compositions for External Application to the Skin Having a Promotion Activity of Collagen Synthesis KR101261731B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020100035335A KR101261731B1 (en) 2010-04-16 2010-04-16 Compositions for External Application to the Skin Having a Promotion Activity of Collagen Synthesis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020100035335A KR101261731B1 (en) 2010-04-16 2010-04-16 Compositions for External Application to the Skin Having a Promotion Activity of Collagen Synthesis

Publications (2)

Publication Number Publication Date
KR20110115803A true KR20110115803A (en) 2011-10-24
KR101261731B1 KR101261731B1 (en) 2013-05-07

Family

ID=45030341

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020100035335A KR101261731B1 (en) 2010-04-16 2010-04-16 Compositions for External Application to the Skin Having a Promotion Activity of Collagen Synthesis

Country Status (1)

Country Link
KR (1) KR101261731B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014158854A1 (en) * 2013-03-14 2014-10-02 Avon Products, Inc Sargassum muticum extracts and methods of use
CN109091433A (en) * 2018-10-22 2018-12-28 广州智尚生物科技有限公司 A kind of composition of oil control and acne removal and its application in cosmetics

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014158854A1 (en) * 2013-03-14 2014-10-02 Avon Products, Inc Sargassum muticum extracts and methods of use
CN109091433A (en) * 2018-10-22 2018-12-28 广州智尚生物科技有限公司 A kind of composition of oil control and acne removal and its application in cosmetics

Also Published As

Publication number Publication date
KR101261731B1 (en) 2013-05-07

Similar Documents

Publication Publication Date Title
CN101686954B (en) Inhibition of AGE formation
KR20180040638A (en) Compositions and methods of use comprising Ampelopsis grosendintata extract and Alvigia ulibrisin extract
EP2666467A1 (en) Extract of aquatic animal cartilage
KR20050114677A (en) Composition for promoting production of type i collagen and/or elastin
CN110691630A (en) Use of extract of rambutan peel for moisturizing skin and/or mucous membranes
CN108883055B (en) Cosmetic use of African chinaberry extract
KR100892888B1 (en) Substances capable of potentiating laminin 5 productivity in epidermal cells and utilization thereof
US6193975B1 (en) Use of potentilla erecta extract in the cosmetic and pharmaceutical field
KR101229927B1 (en) Skin Whitening Composition Using a Litter Extract or a Silk Worm Extract
JP2023052050A (en) Use of nephelium lappaceum extract for increasing the firmness of the skin and/or of the mucous membranes
WO2008105579A1 (en) External composition for skin containing scrophularia buergeriana miq. extract and the use thereof for the skin moisturizing cosmetics
JP4869751B2 (en) Sunburn cell formation inhibitor and DNA damage repair promoter
CN110870880A (en) Topical composition comprising pichia anomala and retinol
JP3172753B2 (en) Biological hyaluronic acid synthesis promoter
JP2003313135A (en) Skin care preparation
JP2012206957A (en) Collagen production promoter
KR101261731B1 (en) Compositions for External Application to the Skin Having a Promotion Activity of Collagen Synthesis
JP2017105777A (en) Compositions for improving skin
KR101170166B1 (en) Compositions for Promotion of Collagen synthesis
KR101094890B1 (en) Compositions for Promotion of Collagen synthesis
KR20140079571A (en) Composition for External Application to the Skin Using an Extract of Pachyrhizus erosus
KR20090030526A (en) Compositions for promotion of collagen synthesis and cosmetics using the same
JP4129475B2 (en) Collagen synthesis promoter and skin external preparation composition containing the same
CN110547975B (en) Cosmetic material composition containing epipinoresinol
KR20180096094A (en) A composition for improving skin wrinkle comprising Cosmos bipinnatus extract

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20160712

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20170413

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20180226

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20190401

Year of fee payment: 7